GlassScriptPhysician profile
Christopher R Mason
NPI 1992947865
$2,849.36
in general payments reported to CMS, 2019-2025
41 companies · $935 in 2025
The $935 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $350 · 2021: $376 · 2022: $129 · 2023: $263 · 2024: $70.84 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $301.04 | 2019-2025 | |
| Amgen INC. | $240.18 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $223.37 | 2019-2025 | Opdivo |
| Pfizer INC. | $188.81 | 2019-2025 | |
| Janssen Biotech, INC. | $188.47 | 2019-2025 | Rybrevant, Darzalex, Imbruvica |
| Alexion Pharmaceuticals, INC. | $165.57 | 2019-2025 | Ultomiris |
| Eisai INC. | $130.17 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $121.61 | 2019-2023 | Enhertu |
| Seagen INC. | $97.24 | 2019-2021 | |
| Astellas Pharma US INC | $96.59 | 2019-2025 | Vyloy |
| Novartis Pharmaceuticals Corporation | $96.15 | 2019-2025 | |
| Daiichi Sankyo INC. | $80.20 | 2023-2025 | Enhertu |
| Genentech USA, INC. | $77.07 | 2019-2025 | Columvi |
| Abbvie INC. | $62.65 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $58.61 | 2021-2025 | Pyrukynd |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.